Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept

Retina

Volumn 35, Issue 4, 2015, Pages 687-694

  Gonzalez, Victor H ^a   Boyer, David S ^b   Schmidt Erfurth, Ursula ^c   Heier, Jeffrey S ^d   Gordon, Carmelina ^e   Benz, Matthew S ^f   Marcus, Dennis M ^g   Sabates, Nelson R ^h   Vitti, Robert ⁱ   Kazmi, Husain ⁱ   Berliner, Alyson J ⁱ   Soo, Yuhwen ⁱ   Zhu, Xiaoping ⁱ   Moini, Hadi ⁱ   Zeitz, Oliver ^j,k   Sandbrink, Rupert ^j,l   Do, Diana V ^m  

^a Valley Retina Institute   (United States)

^b Retina Vitreous Asoiats Medical Group   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TLC Eyecare and Laser Center   (United States)

^f Retina Consultants of Houston ^*  (United States)

^g Southeast Retina Center   (United States)

^h UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

ⁱ REGENERON PHARMACEUTICALS INC   (United States)

^j BAYER PHARMA AG   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l HEINRICH HEINE UNIVERSITY   (Germany)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

DA VINCI; DME; intravitreal aflibercept injection; laser; macular function; microperimetry; retinal sensitivity; VEGF Trap Eye

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LASER; LASER COAGULATION; LOW LEVEL LASER THERAPY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOPHYSIOLOGY; PERIMETRY; PHYSIOLOGY; RETINA; VISUAL FIELD;

AGED; ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84926229333     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000430     Document Type: Article

References (27)

1. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815.
2. Klein R, Moss SE, Klein BE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989;96:1501-1510.
3. World Health Organization (WHO). Global prevalence of diabetes mellitus and its complications. In: Prevention of Blindness From Diabetes Mellitus. WHO Report. Geneva, Switzerland: WHO; 2005. Available at: http://www.who.int/blindness/Prevention% 20of%20Blindness%20from%20Diabetes%20Mellitus-withcover-small.pdf. Accessed March 28, 2012.
4. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number1 Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-1806.
5. Guyer DR, D'Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 1992;113:652-656.
6. Hudson C, Flanagan JG, Turner GS, et al. Influence of laser photocoagulation for clinically significant diabetic macular oedema (DMO) on short-wavelength and conventional automated perimetry. Diabetologia 1998;41:1283-1292.
7. Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990;97:503-510; discussion 510-501.
8. Schatz H, Madeira D, McDonald HR, et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991;109:1549-1551.
9. Javey G, Schwartz SG, Flynn HW Jr. Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res 2012;2012: 548732.
10. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118:1819-1826.
11. Do DV, Nguyen QD, Boyer D, et al. One-Year outcomes of the DA VINCI study of VEGF Trap-eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-1665.
12. Vujosevic S, Midena E, Pilotto E, et al. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci 2006;47: 3044-3051.
13. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
14. Squirrell DM, Mawer NP, Mody CH, et al. Visual outcome after intravitreal ranibizumab for wet age-related macular degeneration: a comparison between best-corrected visual acuity and microperimetry. Retina 2010;30:436-442.
15. Rohrschneider K, Bultmann S, Springer C. Use of fundus perimetry (microperimetry) to quantify macular sensitivity. Prog Retin Eye Res 2008;27:536-548.
16. Rohrschneider K, Springer C, Bultmann S, et al. Microperimetry-comparison between the micro perimeter 1 and scanning laser ophthalmoscope-fundus perimetry. Am J Ophthalmol 2005;139:125-134.
17. Kube T, Schmidt S, Toonen F, et al. Fixation stability and macular light sensitivity in patients with diabetic maculopathy: a microperimetric study with a scanning laser ophthalmoscope. Ophthalmologica 2005;219:16-20.
18. Parravano M, Oddone F, Tedeschi M, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. Retina 2010;30:1017-1024.
19. Richter-Mueksch S, Vecsei-Marlovits PV, Sacu SG, et al. Functional macular mapping in patients with vitreomacular pathologic features before and after surgery. Am J Ophthalmol 2007;144:23-31.
20. Yodoi Y, Tsujikawa A, Kameda T, et al. Central retinal sensitivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007;143:984-994.
21. Vujosevic S, Bottega E, Casciano M, et al. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 2010;30:908-916.
22. Kameda T, Nishijima K, Unoki N, et al. Geographic pattern of central retinal sensitivity after intravitreal triamcinolone for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:3-9.
23. Karacorlu M, Ozdemir H, Senturk F, et al. Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema. Acta Ophthalmol 2010;88: 558-563.
24. Querques G, Bux AV, Martinelli D, et al. Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection. Retina 2009;29:1274-1281.
25. Hatef E, Colantuoni E, Wang J, et al. The relationship between macular sensitivity and retinal thickness in eyes with diabetic macular edema. Am J Ophthalmol 2011;152:400-405 e402.
26. Carpineto P, Ciancaglini M, Di Antonio L, et al. Fundus microperimetry patterns of fixation in type 2 diabetic patients with diffuse macular edema. Retina 2007;27:21-29.
27. Okada K, Yamamoto S, Mizunoya S, et al. Correlation of retinal sensitivity measured with fundus-related microperimetry to visual acuity and retinal thickness in eyes with diabetic macular edema. Eye (Lond) 2006;20:805-809.